Troels R Petersen

Summary

Affiliation: Malaghan Institute of Medical Research
Country: New Zealand

Publications

  1. ncbi Characterization of MHC- and TCR-binding residues of the myelin oligodendrocyte glycoprotein 38-51 peptide
    Troels R Petersen
    Malaghan Institute of Medical Research, Wellington South, New Zealand
    Eur J Immunol 34:165-73. 2004
  2. ncbi Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand
    Troels R Petersen
    Malaghan Institute of Medical Research, Wellington, New Zealand
    Immunol Cell Biol 88:596-604. 2010
  3. ncbi Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines
    Troels R Petersen
    Malaghan Institute of Medical Research, Wellington, New Zealand
    PLoS ONE 6:e17657. 2011
  4. ncbi Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens
    Kathryn J Farrand
    Malaghan Institute of Medical Research, Wellington, New Zealand
    J Immunol 183:7732-42. 2009
  5. ncbi Tumor antigen presentation by dendritic cells
    Troels R Petersen
    Malaghan Institute of Medical Research, Wellington, New Zealand
    Crit Rev Immunol 30:345-86. 2010
  6. ncbi A chimeric T cell receptor with super-signaling properties
    Troels R Petersen
    Malaghan Institute of Medical Research, Wellington, New Zealand
    Int Immunol 16:889-94. 2004
  7. ncbi A chimeric TCR-beta chain confers increased susceptibility to EAE
    Troels R Petersen
    Malaghan Institute of Medical Research, P O Box 7060, Wellington South, New Zealand
    Mol Immunol 44:3473-81. 2007

Collaborators

Detail Information

Publications7

  1. ncbi Characterization of MHC- and TCR-binding residues of the myelin oligodendrocyte glycoprotein 38-51 peptide
    Troels R Petersen
    Malaghan Institute of Medical Research, Wellington South, New Zealand
    Eur J Immunol 34:165-73. 2004
    ..Our results could be useful to design peptides with altered agretopes and epitopes of the MOG(38-51) peptide to study their therapeutic potential in the EAE model...
  2. ncbi Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand
    Troels R Petersen
    Malaghan Institute of Medical Research, Wellington, New Zealand
    Immunol Cell Biol 88:596-604. 2010
    ..Inactivating regulatory T cells and eliciting iNKT cell activation are therefore two useful strategies that can be used in combination to improve anti-tumor immunization with antigen-loaded DCs...
  3. ncbi Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines
    Troels R Petersen
    Malaghan Institute of Medical Research, Wellington, New Zealand
    PLoS ONE 6:e17657. 2011
    ....
  4. ncbi Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens
    Kathryn J Farrand
    Malaghan Institute of Medical Research, Wellington, New Zealand
    J Immunol 183:7732-42. 2009
    ..These data suggest a critical role for the langerin(+) compartment of the CD8alpha(+) DC population in cross-priming and IL-12 production...
  5. ncbi Tumor antigen presentation by dendritic cells
    Troels R Petersen
    Malaghan Institute of Medical Research, Wellington, New Zealand
    Crit Rev Immunol 30:345-86. 2010
    ..In this context, recruiting the activity of cells of the innate immune system to condition host DCs may help elicit more effective T cell-mediated responses...
  6. ncbi A chimeric T cell receptor with super-signaling properties
    Troels R Petersen
    Malaghan Institute of Medical Research, Wellington, New Zealand
    Int Immunol 16:889-94. 2004
    ....
  7. ncbi A chimeric TCR-beta chain confers increased susceptibility to EAE
    Troels R Petersen
    Malaghan Institute of Medical Research, P O Box 7060, Wellington South, New Zealand
    Mol Immunol 44:3473-81. 2007
    ..Investigating the molecular interaction within the TCR complex will help us to identify signalling pathways that can be manipulated to stop the progression of MS...